Jafron Biomedical Co Ltd (300529) — Cash Flow Quality Index
Jafron Biomedical Co Ltd (300529) has a Cash Flow Quality Index of 0.56x as of September 2025. Operating cash flow of CN¥35.34 Million is below net income of CN¥63.51 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore 300529 debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Jafron Biomedical Co Ltd Cash Flow Quality Index (2011–2025)
Historical Cash Flow Quality Index for Jafron Biomedical Co Ltd across 15 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see 300529 cash generation efficiency.
Annual Cash Flow Quality Index for Jafron Biomedical Co Ltd (2011–2025)
Year-by-year earnings quality comparison for Jafron Biomedical Co Ltd.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.35x | CN¥721.22 Million | CN¥532.82 Million | ▲ +5.6% |
| 2024 | 1.28x | CN¥1.05 Billion | CN¥820.20 Million | ▼ -40.5% |
| 2023 | 2.15x | CN¥916.74 Million | CN¥425.72 Million | ▲ +114.6% |
| 2022 | 1.00x | CN¥883.80 Million | CN¥880.92 Million | ▼ -4.0% |
| 2021 | 1.04x | CN¥1.25 Billion | CN¥1.20 Billion | ▼ -4.7% |
| 2020 | 1.10x | CN¥957.49 Million | CN¥873.00 Million | ▲ +6.9% |
| 2019 | 1.03x | CN¥583.50 Million | CN¥568.69 Million | ▲ +7.1% |
| 2018 | 0.96x | CN¥384.08 Million | CN¥400.95 Million | ▼ -10.4% |
| 2017 | 1.07x | CN¥304.10 Million | CN¥284.45 Million | ▲ +21.0% |
| 2016 | 0.88x | CN¥178.64 Million | CN¥202.12 Million | ▼ -13.7% |
| 2015 | 1.02x | CN¥205.18 Million | CN¥200.44 Million | ▲ +19.3% |
| 2014 | 0.86x | CN¥137.35 Million | CN¥160.05 Million | ▼ -18.4% |
| 2013 | 1.05x | CN¥133.33 Million | CN¥126.78 Million | ▼ -12.5% |
| 2012 | 1.20x | CN¥120.25 Million | CN¥100.02 Million | ▲ +18.2% |
| 2011 | 1.02x | CN¥77.06 Million | CN¥75.76 Million | — |